Search

Displaying results 2001 - 2010 of 8696 in total
  1. Drug

    Paraldehyde

    go.drugbank.com/drugs/DB09117
    ApprovedWithdrawn

    Paraldehyde is used as an ingredient in some cough medicines as an expectorant, but its efficacy for this indication has not been confirmed and its use as an expectorant may possibly be due to a placebo … It is classified as a central nervous system (CNS) depressant and has also been found to be an effective anticonvulsant, hypnotic and sedative agent due to its CNS depressant properties.

  2. Drug

    Oteracil

    go.drugbank.com/drugs/DB03209
    ApprovedInvestigational

    The main active ingredient in Teysuno is [DB09256], a pro-drug of [DB00544] (5-FU), which is a cytotoxic anti-metabolite drug that acts on rapidly dividing cancer cells. … Oteracil's main role within Teysuno is to reduce the activity of 5-FU within normal gastrointestinal mucosa, and therefore reduce's gastrointestinal toxicity [L933].

  3. Drug

    Bromothalonil

    go.drugbank.com/drugs/DB14199
    Approved

    Sensitivity to Bromothalonil may be identified with a clinical patch test. … Bromothalonil, also known as Methyldibromo glutaronitrile (MDBGN), is a widely used preservative that can be found in many personal hygiene and industrial products.

  4. Drug

    Suprofen

    go.drugbank.com/drugs/DB00870
    ApprovedWithdrawn

    An ibuprofen-type anti-inflammatory analgesic and antipyretic. It inhibits prostaglandin synthesis and has been proposed as an anti-arthritic. It is no longer approved for use in the United States.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 InhibitorsSynonyms: p-2-thenoylhydratropic acid, (±)-2-(p-(2-thenoyl)phenyl)propionic acid
  5. Drug

    Ceftolozane

    go.drugbank.com/drugs/DB09050
    ApprovedInvestigational

    [L6685] It was approved by the FDA in 2014 for use in combination with [Tazobactam] for the treatment of serious infections, such as intra-abdominal infections and complicated urinary tract infections. … [A179422] Most recently, in June 2019, ceftolozane-tazobactam was approved for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.

    Mixtures: ZERBAXA POWDER FOR SOLUTION FOR INJECTION 1G/0.5G, Zerbaxa 1.5g powder for solution for injection
  6. Drug

    Phenyl salicylate

    go.drugbank.com/drugs/DB11071
    Approved

    It is an active ingredient in some pharmaceutical products as a mild analgesic for pain relief by releasing salicylate (found in [DB00945] ). … Phenyl salicylate may also be found in some antiseptic agents [L2467]. It is synthesized by heating salicylic acid with phenol [L2468], [MSDS].

    Mixtures: UR N-C Urinary Antiseptic
  7. Drug

    Human papillomavirus type 52 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10313
    ApprovedInvestigational

    It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 52 The vaccine is prepared from the purified virus-like particles … Human papillomavirus type 52L1 capsid protein antigen is contained in Gardasil is a vaccine for intramuscular injection.

    Mixtures: GARDASIL 9 SUSPENSION FOR INJECTION
  8. Drug

    Torasemide

    go.drugbank.com/drugs/DB00214
    ApprovedInvestigational

    [A174463] Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent.[A319] Torasemide was first approved for clinical use by the FDA in 1993.[L5257]

    Categories: Antihypertensive Agents Indicated for Hypertension, Cytochrome P-450 Substrates
  9. Drug

    Alitretinoin

    go.drugbank.com/drugs/DB00523
    Approved

    Tretinoin, also known as retinoic acid and derived from maternal vitamin A, is essential for normal growth; and embryonic development. An excess of tretinoin can be teratogenic. … It has also been approved for use in promyelocytic leukemia (leukemia, promyelocytic, acute).

    Categories: P-glycoprotein substrates, Retinoids for cancer treatment
  10. Drug

    Selpercatinib

    go.drugbank.com/drugs/DB15685
    ApprovedInvestigational

    [A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific … [A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers.

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates